Of 22 IGHV1-69 B-CLL patient samples, 6 (27.3%) reacted with HIV-1 Envs; 3 (13.6%) reacted with ADA aldrithol-2 (AT-2)-inactivated virions, 1 (4.5%) with deglycosylated JRFL gp140, and 4 (18.2%) with one or more gp41 epitope peptides. This evidence concerns the gene ADA and B-cell chronic lymphocytic leukemia.